
Shares of bio-tech firm Bio-Techne TECH.O fall about 9% at $55.44 in premarket trading
Reports Q1 sales drop 1% to $286.6 million, missing analysts' estimates of $291.2 million - data compiled by LSEG
Posts Q1 adjusted EPS in line with estimate of 42 cents
"We observed encouraging signs of stabilization in our US academic end market," says CEO Kim Kelderman, adding "funding headwinds persisted for emerging biotech companies"
As of last close stock down 15.2% YTD